A prospective multi-center single-arm study of EBV-associated lymphoproliferative disease by allogeneic EBV specific DC-CTL infusion

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900028055

Enrollment

Unknown

Registered

2019-12-08

Start date

2014-11-01

Completion date

Unknown

Last updated

2019-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory or relapse EBV-associated lymphoproliferative disease

Interventions

Case series:EBV-DC-CTL

Eligibility

Sex/Gender

All

Age

1 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. EBV-associated lymphoproliferative diseases are confirmed by pathology histomorphology and immunohistochemistry, and EBER positive are determined using in situ hybridization method; 2. EB virus DNA in peripheral blood is positive; 3. routine treatment of peripheral blood EBV is invalid; 4. Eastern Cancer Collaboration (ECOG) Physical Status Rating 0-2.

Exclusion criteria

Exclusion criteria: 1. patients had a severe transfusion reaction or transfusion related to GVHD; 2. patients had hepatitis B active infection or HIV antibody positive; 3. patients had any other serious active or psychiatric disorder; 4. patients are already pregnant or breastfeeding; 5. Comprehensive assessment of life expectancy is less than 3 months.

Design outcomes

Primary

Measure	Time frame
EBV copies;Lesion size;	—

Countries

China

Contacts

Public ContactXinan Cen

Peking University First Hospital

cenxn@hotmail.com+86 10 83575680

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026